한글목차

세계의 지혈제 시장은 2024년에 30억 1,000만 달러로 평가되었습니다. 2032년에는 41억 5,000만 달러에 이를 것으로 예측되며, 예측 기간 2025-2032년의 CAGR은 4.2%를 나타낼 전망입니다.

지혈제는 상처나 수술 부위의 출혈을 예방하거나 지혈하는 데 도움이 되도록 고안된 물질입니다. 지혈제는 출혈을 멈추는 신체의 메커니즘인 지혈 과정에서 발생하는 자연적인 과정을 촉진하는 방식으로 작용합니다. 지혈제는 혈장 단백질, 칼슘 이온 및 혈소판과 상호 작용하여 혈전 형성을 촉진하고 출혈을 조절합니다.

지혈제는 피브리노겐에서 피브린으로의 전환을 강화하여 보다 효율적이고 튼튼한 혈전을 형성합니다. 이러한 제제는 일반적으로 수술 환경, 외상 치료 및 출혈 관리가 중요한 의료 절차 중에 사용되며, 보다 빠르고 안정적인 지혈을 촉진하는 데 중요한 도움을 제공합니다.

시장 역학

촉진요인과 억제요인

수술 건수 증가

전 세계적으로 수술 건수가 증가하는 것이 지혈제 시장을 이끄는 핵심 요인입니다. 수술 건수가 증가함에 따라 복잡한 수술 중 출혈을 제어하기 위한 효과적인 지혈제의 필요성이 증가하고 있습니다. 이러한 추세는 종종 외과적 치료가 필요한 심혈관 질환 및 암과 같은 만성 질환의 유병률 증가로 인해 더욱 가속화되고 있습니다. 예를 들어, 2023년 미국 국립보건원은 매년 약 40만 건의 CABG 수술이 시행되어 가장 일반적으로 시행되는 주요 수술이 될 것이라고 발표했습니다.

수술을 받는 환자가 증가함에 따라 신뢰할 수 있는 지혈 솔루션에 대한 수요도 계속 증가하고 있으며, 이는 시장 확대에 기여하고 있습니다. 예를 들어, 2024년 미국 국립보건원에 따르면 고관절 및 슬관절 전치환술은 미국에서 가장 많이 시행되는 수술 중 하나로, 약 700만 명의 미국인이 고관절 또는 슬관절 전치환술을 받고 있으며 매년 100만 건 이상의 고관절 및 슬관절 전치환술이 시행되고 있는 것으로 추산됩니다.

젤, 드레싱, 파우더와 같은 지혈제는 이러한 수술에서 지혈을 지원하는 데 점점 더 많이 사용되고 있으며, 현대 수술에서 필수적인 요소로 자리 잡고 있습니다. 특히 높은 정밀도와 빠른 회복이 요구되는 수술에서 효과적인 지혈이 필요하기 때문에 지혈제는 수술에서 중요한 구성 요소가 되고 있습니다. 따라서 수술 기술이 계속 발전하고 전 세계적으로 수술량이 증가함에 따라 지혈제 시장은 빠르게 확대될 것으로 예상됩니다.

지혈제와 관련된 부작용

지혈제와 관련된 부작용은 환자의 안전과 치료 효과에 대한 우려를 불러일으키며 시장 성장에 큰 걸림돌이 되고 있습니다. 이러한 제제는 두통, 메스꺼움, 호흡기 문제, 아나필락시스와 같은 심각한 알레르기 반응 등 다양한 부작용을 일으킬 수 있어 의료진이 사용을 꺼릴 수 있습니다. 또한 이러한 제품을 부적절하게 사용하거나 과도하게 사용하면 감염 및 조직 손상과 같은 합병증이 발생하여 수술 결과가 복잡해지고 광범위한 채택이 제한될 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 수술 건수 증가
  • 성장 억제요인
    • 지혈제와 관련된 부작용과 안전성 우려
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 특허 분석
• 규제 분석
• SWOT 분석
• 충족되지 않은 요구 사항

제6장 재료별

• 키토산 기반
• 젤라틴 기반
• 콜라겐 기반
• 산화 재생 셀룰로오스(ORC)
• 유동성 지혈재
• 기타

제7장 형태별

• 파우더
• 겔
• 스폰지
• 매트릭스
• 시트, 패드

제8장 투여 경로별

• 국소
• 정맥 주사
• 기타

제9장 용도별

• 일반 수술
• 심장혈관 수술
• 정형외과
• 기타

제10장 최종 사용자별

• 병원
• 클리닉
• 진단 실험실
• 기타

제11장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 구도

• 경쟁 시나리오
• 시황, 점유율 분석
• M&A 분석

제13장 기업 프로파일

• Becton, Dickinson, and Company
  • 기업 개요
  • 제품 포트폴리오와 개요
  • 재무 개요
  • 주요 발전
• Aegis Lifesciences
• Baxter
• Teleflex Incorporated
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• 3-D Matrix Medical Technology
• Medcura
• Ferrosan Medical Devices A/S
• Delta Surgical

제14장 부록

제15장 문의

영문목차

The global hemostatic agents market reached US$ 3.01 billion in 2024 and is expected to reach US$ 4.15 billion by 2032, growing at a CAGR of 4.2% during the forecast period 2025-2032.

Hemostatic agents are substances designed to help prevent or stop bleeding at a wound or surgical site. They work by facilitating the natural processes that occur during hemostasis, which is the body's mechanism for stopping bleeding. Hemostatic agents interact with plasma proteins, calcium ions, and blood platelets to promote clot formation and control bleeding.

Hemostatic agents enhance this fibrinogen-to-fibrin conversion, ensuring a more efficient and durable clot. These agents are commonly used in surgical settings, trauma care, and during medical procedures where bleeding control is critical, providing a crucial aid in promoting faster and more reliable hemostasis.

Market Dynamics: Drivers & Restraints

Increasing Surgical Volume

The growing number of surgical procedures worldwide is a key factor driving the hemostatic agents market. As surgical volumes rise, there is an increasing need for effective hemostatic agents to control bleeding during complex surgeries. This trend is further fueled by the rising prevalence of chronic conditions, such as cardiovascular diseases and cancer, that often require surgical treatment. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure.

As more patients undergo surgery, the demand for reliable hemostatic solutions continues to grow, contributing to the market's expansion. For instance, according to the National Institute of Health in 2024, total hip and knee arthroplasty surgeries are two of the most common procedures performed in the United States, with an estimated 7 million Americans living with a total hip or knee replacement and over 1 million total hip and knee replacements performed each year.

Hemostatic agents, such as gels, dressings, and powders, are increasingly being used to support hemostasis in these procedures, making them an essential component in modern surgical practices. The need for effective hemostasis, especially in surgeries requiring high precision and quick recovery, is making these agents important components in surgeries. Thus, as surgical techniques continue to evolve and surgical volumes increase worldwide, the market for hemostatic agents is expected to expand rapidly

Adverse Effects Associated with the Hemostatic Agents

Adverse effects associated with hemostatic agents pose a significant challenge to their market growth, raising concerns about patient safety and treatment effectiveness. These agents can lead to various side effects, including headaches, nausea, respiratory issues, and potentially severe allergic reactions such as anaphylaxis, which may discourage healthcare providers from using them. Furthermore, complications like infections and tissue damage can occur from improper application or overuse of these products, complicating surgical outcomes and limiting their broader adoption.

Segment Analysis

The global hemostatic agents market is segmented based on material, form, route of administration, application, end-user, and region.

Type:

Chitosan-based segment is expected to dominate the global hemostatic agents market share

Chitosan-based hemostatic agents segment is expected to hold a dominant position in the hemostatic agents market due to several key factors. Chitosan's unique biocompatibility, tunable mechanical properties, and ease of handling make it an ideal choice for use in hemostatic applications. Its injectability allows for minimally invasive procedures, which enhances its appeal in various surgical settings.

Chitosan-based hemostatic hydrogels are commonly used for controlling bleeding due to their exceptional biocompatibility, adjustable mechanical properties, injectability, and ease of use. Additionally, chitosan (CS) can absorb red blood cells and stimulate platelet activation, enhancing the process of hemostasis. The growing demand for natural and biocompatible materials in healthcare, along with its proven efficacy in controlling bleeding during surgeries, positions chitosan-based hemostatic agents as a leading solution in the market. Additionally, advancements in chitosan-based formulations are further driving the segment's growth, making it a preferred choice for healthcare providers.

Geographical Analysis

North America is expected to hold a significant position in the global hemostatic agents market share

North America is expected to hold a significant position in the global hemostatic agents market due to several high rates of surgical procedures which include both elective and emergency surgeries, leading to higher demand for hemostatic agents to control bleeding during and after these procedures. For instance, according to the National Institute of Health report in 2023, in the United States, 1 in 9 individuals living in households reported having at least one surgical procedure in 2023. The highest rates were observed among individuals aged 65 and older, as well as Medicare beneficiaries, with approximately 1 in 5 people in both groups reporting having undergone surgery.

The growing prevalence of chronic conditions like cardiovascular diseases, diabetes, and cancer, all which increase the demand for effective hemostatic solutions. Furthermore, North America comprises several key market players and a strong focus on medical innovation, leading to the development and adoption of cutting-edge hemostatic products. For instance, in July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding. The region also has well-established regulatory frameworks, which ensure the safety and effectiveness of these agents, further boosting their use.

Competitive Landscape

The major global players in the hemostatic agents market include Becton, Dickinson, and Company, Aegis Lifesciences, Baxter, Teleflex Incorporated, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Key Developments

• In April 2023, Olympus announced the launch of EndoClot Adhesive (ECA), EndoClot Polysaccharide Hemostatic Spray (PHS) and EndoClot Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region. This innovative portfolio was developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.
• In September 2024, Toagosei Co., Ltd. launched a dental hemostatic agent for tooth extraction sockets called "Aron Cure Dental". Aron Cure Dental is a new concept of dental hemostatic agent. It stops bleeding after tooth extraction with a hydrogel polymer sponge.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Hemostatic Agents market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Material
• 3.2. Snippet by Form
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of chronic pain conditions
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse effects and safety concerns associated with Hemostatic Agents
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Material

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Material
  • 6.1.2. Market Attractiveness Index, By Material
• 6.2. Chitosan-based*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Gelatine-based
• 6.4. Collagen-based
• 6.5. Oxidized Regenerated Cellulose (ORC)
• 6.6. Flowable Hemostats
• 6.7. Others

7. By Form

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
  • 7.1.2. Market Attractiveness Index, By Pain Type
• 7.2. Powder*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Gel
• 7.4. Sponges
• 7.5. Matrix
• 7.6. Sheet & Pads

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Topical*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intravenous
• 8.4. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. General Surgery*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cardiovascular Surgery
• 9.4. Orthopedic Surgery
• 9.5. Others

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Clinics
• 10.4. Diagnostic Laboratories
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Becton, Dickinson, and Company*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Aegis Lifesciences
• 13.3. Baxter
• 13.4. Teleflex Incorporated
• 13.5. Johnson & Johnson Services, Inc.
• 13.6. Pfizer Inc.
• 13.7. 3-D Matrix Medical Technology
• 13.8. Medcura
• 13.9. Ferrosan Medical Devices A/S
• 13.10. Delta Surgical

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services

15. Contact Us